The prognosis of myocardial infarction (STEMI & NSTEMI) in patients with metabolic syndrom
Author(s): Dr. Madhu Kumar MH, Dr. Sudeep Jayaram, Dr. Nirmal Kumar Sharma and Dr. Sourabh Chittora
Abstract: A recent review of insulin resistance syndrome (IRS) revealed a rapid escalation of metabolic syndrome among Indians and that the prevalence of predominant component of metabolic syndrome varied from region to region in Indians. Studies on the pathophysiology of this syndrome revealed close to a six-fold increase in cardiovascular mortality. Standardized definition of MI and clinical outcome will be used. A final diagnosis of MI will be made in the presence of serial increases in serum biochemical markers of cardiac necrosis, associated with typical electrocardiographic changes and/or typical symptoms. 27.27% (20) of patients of MI with METS were obese (BMI ≥ 30kg/m2) compared to 2.74% (2) of the patients of MI without METS, which was statistically significant (p value <0.05). There was no significant difference in the other factors like use of thrombolytic therapy, LDL-C and the ST- elevation MI (STEMI) in both the groups.
Dr. Madhu Kumar MH, Dr. Sudeep Jayaram, Dr. Nirmal Kumar Sharma, Dr. Sourabh Chittora. The prognosis of myocardial infarction (STEMI & NSTEMI) in patients with metabolic syndrom. Int J Adv Res Med 2021;3(2):01-04. DOI: 10.22271/27069567.2021.v3.i2a.206